loading
Schlusskurs vom Vortag:
$45.12
Offen:
$45.18
24-Stunden-Volumen:
8.51M
Relative Volume:
3.03
Marktkapitalisierung:
$7.61B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-18.61
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+7.50%
1M Leistung:
+35.53%
6M Leistung:
+60.27%
1J Leistung:
+78.02%
1-Tages-Spanne:
Value
$44.20
$45.48
1-Wochen-Bereich:
Value
$41.30
$45.48
52-Wochen-Spanne:
Value
$21.72
$45.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Firmenname
Bridgebio Pharma Inc
Name
Telefon
(650) 391-9740
Name
Adresse
3160 PORTER DR., PALO ALTO, CA
Name
Mitarbeiter
730
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BBIO
Bridgebio Pharma Inc
44.86 7.61B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-31 Eingeleitet Redburn Atlantic Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-03 Eingeleitet Oppenheimer Perform
2024-09-04 Eingeleitet Piper Sandler Overweight
2024-03-21 Fortgesetzt Raymond James Outperform
2024-01-31 Eingeleitet BMO Capital Markets Market Perform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-07 Eingeleitet Citigroup Buy
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-07-18 Herabstufung Jefferies Buy → Hold
2023-04-19 Eingeleitet Evercore ISI Outperform
2023-02-06 Eingeleitet Cowen Outperform
2021-12-27 Bestätigt Mizuho Buy
2021-12-27 Bestätigt SVB Leerink Outperform
2021-09-10 Hochstufung BofA Securities Neutral → Buy
2021-05-21 Eingeleitet UBS Buy
2021-03-22 Bestätigt Goldman Buy
2021-02-22 Fortgesetzt JP Morgan Overweight
2021-02-09 Fortgesetzt Goldman Buy
2021-01-11 Bestätigt H.C. Wainwright Buy
2020-12-10 Bestätigt H.C. Wainwright Buy
2020-06-25 Eingeleitet BofA/Merrill Neutral
2020-05-19 Eingeleitet BTIG Research Buy
2020-04-13 Eingeleitet H.C. Wainwright Buy
2020-02-19 Eingeleitet Mizuho Buy
2019-07-26 Eingeleitet Raymond James Outperform
2019-07-22 Eingeleitet BMO Capital Markets Outperform
2019-07-22 Eingeleitet Goldman Buy
2019-07-22 Eingeleitet JP Morgan Overweight
2019-07-22 Eingeleitet Jefferies Buy
2019-07-22 Eingeleitet Piper Jaffray Overweight
2019-07-22 Eingeleitet SVB Leerink Outperform
Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Comments on BBIO FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis

Jun 10, 2025
pulisher
Jun 09, 2025

BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com

Jun 09, 2025
pulisher
Jun 07, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 05, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025

Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):